Related Experiment Video
Updated: Jan 24, 2026

Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
Intranasal Temperature Modulation Device in Awake Healthy Volunteers: A First In-Human Safety and Tolerability Study
Alan S Nova1, Neeraj Badjatia2
1Ascension Health, Austin, Texas, USA.
Abstract:
Fever after brain injury is a known contributor to poor outcomes; however, temperature-modulating devices (TMDs), such as surface and intravascular systems, face significant limitations, including delayed deployment, invasiveness, patient discomfort, skin integrity issues, frequent induction of shivering, and the need for sedation, all of which hinder timely neuroprotective therapy and confound neurological assessments. This first in-human study evaluated the safety and tolerability of an intranasal TMD, which delivers thermoelectrically temperature-regulated air via a nasal cannula to affect the core temperature. Five healthy, awake adult volunteers (median age 34 years old, 57.1% men) underwent intranasal cooling with 5°C cooled air delivered at flow rates between 15 and 58 liters per minute. The primary endpoints were safety and tolerability. The reduction in core body temperature was recorded using an esophageal temperature probe. No pharmacological agents or sedatives were administered to the patient. All participants exhibited a consistent downward trend in core body temperature, with an average reduction of 0.7°C at 30 minutes and 1.2°C at 60 minutes. Notably, no shivering or adverse events related to the intranasal TMD were reported. Cooling was well-tolerated, with esophageal probe placement being the only limiting factor for full protocol completion in some subjects. Participants remained fully conscious and communicative throughout the therapy. This intranasal TMD achieved clinically relevant core cooling without triggering shivering or requiring sedation, thereby addressing the key barriers associated with traditional TMDs. These promising early results support further investigation of this intranasal TMD in patients with acute neurological injury. Future studies should explore its performance in critical care and prehospital environments, where time-sensitive neuroprotection is most impactful.
More Related Videos
07:48Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
Published on: May 16, 2016
05:28A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System
Published on: August 15, 2019
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Survey Safety
Household Wiring And Electrical Safety
Body Temperature
The average body temperature is approximately 37°C (98.6°F) and typically ranges from 36.1–37.2°C...
Body Temperature
Effects of Temperature on Free Energy